567-01-1 Usage
Description
3β,5α-THDOC is a neurosteroid. It inhibits seizures induced by pilocarpine, but not pentylenetetrazol (PTZ; ), in mice (ED50s = 45.9 and >100 mg/kg, respectively). 3β,5α-THDOC has been found in the urine of women during the third trimester of pregnancy.
Uses
Different sources of media describe the Uses of 567-01-1 differently. You can refer to the following data:
1. 3β,5α-Tetrahydrodeoxycorticosterone is a novel derivative of the steroid Dehydroepiandrosterone (DHEA), a known uncompetitive inhibitor of Glucose 6-Phosphate Dehydrogenase (G6PD). Studies have shown
that 3β,5α-Tetrahydrodeoxycorticosterone may have potential function in the modulation of calcium and GABAA-gated chloride channel currents found in rat and guinea-pig neurons.
2. 3β,5α-Tetrahydrodeoxycorticosterone is a novel derivative of the steroid Dehydroepiandrosterone (DHEA), a known uncompetitive inhibitor of Glucose 6-Phosphate Dehydrogenase (G6PD). Studies have shown that 3β,5α-Tetrahydrodeoxycorticosterone may have potential function in the modulation of calcium and GABAA-gated chloride channel currents found in rat and guinea-pig neurons.
in vitro
epiallopregnanolone showed no effects on the gaba-mediated chloride flux through several types of recombinant gaba receptors. epiallopregnanolone inhibited the allopregnanolone-stimulated gaba-mediated chloride flux through gabaa receptors. epiallopregnanolone antagonized the inhibitory effects of allopregnanolone and ethanol on the population spike in the ca1 region of the hippocampal brain slices [1]. epiallopregnanolone selectively blocked the allopregnanolone inhibition of the population spike in the rat hippocampal ca1[3].
in vivo
in rats trained to discriminate either 0.8g/kg or 1.2 g/kg ethanol, 100 mg/kg epiallopregnanolone treatment decreased the maximum effect by 40% and 54% ethanol lever, respectively. epiallopregnanolone significantly decreased response rates when compared with control condition [1].
references
[1] ginsburg b c, lamb r j. alphaxalone and epiallopregnanolone in rats trained to discriminate ethanol[j]. alcoholism: clinical and experimental research, 2005, 29(9): 1621-1629.[2] macdonald r l, olsen r w. gabaa receptor channels[j]. annual review of neuroscience, 1994, 17(1): 569-602.[3] wang m, bckstrm t, landgren s. epiallopregnanolone selectively blocks the allopregnanolone inhibition of the population spike in the rat hippocampal ca1[j]. acta physiologica scandinavica, 1999, 167(2): a5-a5.
Check Digit Verification of cas no
The CAS Registry Mumber 567-01-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,6 and 7 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 567-01:
(5*5)+(4*6)+(3*7)+(2*0)+(1*1)=71
71 % 10 = 1
So 567-01-1 is a valid CAS Registry Number.
567-01-1Relevant articles and documents
INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS
-
Page/Page column 41-42, (2018/06/06)
The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase
Hamilton, Niall M.,Dawson, Martin,Fairweather, Emma E.,Hamilton, Nicola S.,Hitchin, James R.,James, Dominic I.,Jones, Stuart D.,Jordan, Allan M.,Lyons, Amanda J.,Small, Helen F.,Thomson, Graeme J.,Waddell, Ian D.,Ogilvie, Donald J.
supporting information; experimental part, p. 4431 - 4445 (2012/09/11)
Novel derivatives of the steroid DHEA 1, a known uncompetitive inhibitor of G6PD, were designed, synthesized, and tested for their ability to inhibit this dehydrogenase enzyme. Several compounds with approximately 10-fold improved potency in an enzyme assay were identified, and this improved activity translated to efficacy in a cellular assay. The SAR for steroid inhibition of G6PD has been substantially developed; the 3β-alcohol can be replaced with 3β-H-bond donors such as sulfamide, sulfonamide, urea, and carbamate. Improved potency was achieved by replacing the androstane nucleus with a pregnane nucleus, provided a ketone at C-20 is present. For pregnan-20-ones incorporation of a 21-hydroxyl group is often beneficial. The novel compounds generally have good physicochemical properties and satisfactory in vitro DMPK parameters. These derivatives may be useful for examining the role of G6PD inhibition in cells and will assist the future design of more potent steroid inhibitors with potential therapeutic utility.
